- Liver cancer is one of the deadliest malignancies, with an overall five-year survival rate of roughly 20%[8].
- There are two distinct diseases: primary tumours that begin in liver cells (hepatocellular carcinoma) and metastases that spread from cancer elsewhere.
- Most cases trace to a small set of causes: chronic hepatitis B or C, cirrhosis, heavy alcohol use, obesity, and fatty liver disease[5].
- The immune system is a decisive variable. Mushroom polysaccharides have been shown to mobilise NK cells and T-lymphocytes that fight tumour progression[5].
What the liver does
The liver is one of the largest and most important internal organs, and its core job is processing everything you eat and drink. It stores nutrients, clears worn-out cells and waste from the blood, filters toxins from medication and alcohol, and produces the bile that lets you digest fat. When a tumour takes hold here, it disrupts a chemical factory the rest of the body depends on.
Metastases vs primary tumours
Liver cancer is really two different diseases. In one, the tumour originates in the liver itself, usually in the main liver cells, the hepatocytes. This is called hepatocellular carcinoma (HCC) and it is by far the most common primary liver cancer[1]. In the other, the tumour in the liver has travelled there from a cancer somewhere else in the body, in other words, liver metastases seeded from another organ. The distinction matters enormously for treatment and prognosis.
Why it happens
The most common causes of liver cancer are remarkably consistent:
- Obesity
- Alcohol
- Smoking
- Long-term hepatitis B[9]
- Long-term hepatitis C
Fatty liver disease is sometimes listed as a separate cause, but its drivers are almost identical to those of liver cancer itself: alcohol and other toxins, overeating, excess fructose, elevated triglycerides, high blood glucose, and chronic hepatitis B and C[5]. In practice, the same metabolic and viral pressures that scar the liver are the ones that eventually push cells toward malignancy.
The four stages
Liver cancer is grouped into four stages[6]:
| Stage | What it means |
|---|---|
| Stage 1 (very early, 1A/1B) | A single tumour confined to the liver, smaller than 2 cm. |
| Stage 2 (early) | One tumour 5 cm or smaller, or more than one tumour under 3 cm. May have reached blood vessels. |
| Stage 3 (intermediate, 3A/3B) | More than one tumour, at least one larger than 5 cm. May have spread to lymph nodes, large blood vessels, or another organ. |
| Stage 4 (advanced, 4A/4B) | Cancer has metastasised to distant sites such as the lungs or bones, as well as lymph nodes. |
Survival and prognosis
Although five-year survival for liver cancer has risen significantly over the past two decades[7], the outlook remains sobering. Prognosis depends on several factors working together: the stage at diagnosis, the number of lesions, whether metastases are present, the health of the surrounding liver tissue, and the patient's overall condition.
The American Cancer Society puts the overall five-year survival rate for liver cancer at around 20%[8]. That single number hides enormous variation: caught at stage 1, the picture is very different from stage 4.
Can you improve the odds?
Prognosis is not determined by stage and treatment method alone. The body's own ability to fight the disease is an equally important variable. The immune system plays a decisive role: it recognises altered cells, slows the spread of metastases, and helps the body recover after surgery or chemotherapy.
Research confirms that certain mushroom polysaccharides can strengthen the immune response during cancer[3][4]. These active compounds help the body mobilise its defensive cells more effectively, the NK (natural killer) cells and T-lymphocytes that directly attack tumour progression[5]. In hepatocellular carcinoma specifically, lentinan has been studied in combination with standard interventions such as radiofrequency ablation and transarterial chemoembolisation[5].
Clinical experience suggests that patients who combine standard treatment with immune-supporting supplements more often achieve better response rates. Supplements are not a cure for cancer, but they are used as an adjunct, alongside primary treatment, never as a replacement for it.
Concentrated mushroom polysaccharides are studied for their role in activating NK cells and macrophages during oncological treatment.
Lentinan AXT by Zenius Labs™ →In its early stages liver cancer often causes no symptoms. Later it may produce pain in the upper-right abdomen, weight loss, loss of appetite, nausea, jaundice, and general weakness. Regular check-ups are especially important for people in high-risk groups.
Yes. Immune support is particularly important because the liver plays a central role in the body's detoxification and immune function. Concentrated mushroom polysaccharide extracts may help activate NK cells and macrophages[4]. It is worth choosing a concentrated, multi-extract formula such as Lentinan AXT by Zenius Labs™.
The most common are chronic hepatitis B or C, liver cirrhosis, heavy alcohol use, and fatty liver disease. Regular screening helps catch the disease at an earlier, more treatable stage.
Diagnosed early, liver cancer can be treated successfully with surgery or a liver transplant. Even after treatment, however, the risk of recurrence stays high, which is why long-term immune support with concentrated mushroom polysaccharide formulas matters.
A liver-sparing diet is very important. Quality animal fats (eggs, butter, wild-caught fish), plenty of vegetables, and avoidance of alcohol, sugar, and processed foods are generally recommended.
- Kawarada Y et al. Significance of multidisciplinary therapy for hepatocellular carcinoma. Cancer chemotherapy and pharmacology . 1992. PubMed
- Zou Y et al. A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine . 2015. PubMed
- Khinsar KH et al. Anti-tumor effect of polysaccharide from Pleurotus ostreatus on H22 mouse Hepatoma ascites in-vivo and hepatocellular carcinoma in-vitro model. AMB Express . 2021. PubMed
- Li GL et al. The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway. Food & function . 2023. PubMed
- Yang P et al. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in therapy . 2008. PubMed
- American Cancer Society. Liver Cancer Stages. cancer.org
- American Cancer Society. Survival Rates for Liver Cancer. cancer.org
- American Cancer Society. Survival Rates for Liver Cancer (5-year relative survival). cancer.org
- Mani SKK et al. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells. Genes . 2018. PubMed